The abstract is read at the publisher; the summary is JClub's.
In 159 pediatric patients with PAX5-rearranged B-acute lymphoblastic leukemia, end-of-induction MRD positivity links to worse outcomes, with 4-year EFS 72.6% ± 5.7% overall.
- Why it matters: Pediatric PAX5-rearranged ALL is a newer molecular subtype, and clinical evidence on how measurable residual disease (MRD) shapes prognosis has been limited.
- What they did: The study analyzed AIEOP-BFM ALL cohorts (2001–2024), comparing PAX5-r (n = 96) versus non-PAX5-r (n = 1948) and stratifying 4-year EFS by standard-risk, medium-risk (MR), and high-risk (HR) groups; it also used whole-transcriptome sequencing and PDX drug testing.
- The result: PAX5-r patients had higher hyperleukocytosis (22.9% vs 8%; P< .001) and more IKZF1plus profiles (14.7% vs 7.8%; P = .0015), while MRD response differed mainly by risk: 4-year EFS was 100% (standard-risk) versus 63.4% ± 9.7% (MR) and 63.3% ± 10% (HR); FLT3 overexpression and FLT3 inhibitor sensitivity, including gilteritinib plus dexamethasone synergy, were shown in PDX models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.